Patents by Inventor Demetrios Kalaitzidis

Demetrios Kalaitzidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210108174
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 15, 2021
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • Publication number: 20210085718
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 25, 2021
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20210079347
    Abstract: A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).
    Type: Application
    Filed: September 4, 2020
    Publication date: March 18, 2021
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Hanspeter Waldner
  • Publication number: 20210060072
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
    Type: Application
    Filed: May 10, 2019
    Publication date: March 4, 2021
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
  • Patent number: 10881689
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: January 5, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20200405761
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: July 29, 2020
    Publication date: December 31, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20200405764
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 31, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10857184
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 8, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20200330518
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: July 8, 2020
    Publication date: October 22, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10736919
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 11, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Patent number: 10729725
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: August 4, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20200063100
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
    Type: Application
    Filed: May 10, 2019
    Publication date: February 27, 2020
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee DEQUÉANT, Zinkal Samir PADALIA
  • Publication number: 20190365809
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 6, 2019
    Publication date: December 5, 2019
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20190365808
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 5, 2019
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Publication number: 20190314414
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • Publication number: 20190314413
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • Publication number: 20180325955
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein